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Abstract
Associations between interleukin 6 (IL-6) polymorphisms and Alzheimer’s disease (AD) remain controversial and ambiguous.
The aim of this meta-analysis is to explore more precise estimations for the relationship between IL-6-174 G/C and -572 C/G
polymorphisms and risk for AD. Electronic searches for all publications in databases PubMed and EMBASE were conducted
on the associations between IL-6 polymorphisms and risk for AD until January 2012. Odds ratio (OR) and 95% confidence
intervals (CIs) were calculated using fixed and random effects models. Twenty-seven studies were included with a total of
19,135 individuals, involving 6,632 AD patients and 12,503 controls. For IL-6-174 G/C polymorphism, the combined results
showed significant differences in recessive model (CC vs. CG+GG: OR=0.65, 95%CI=0.52–0.82). As regards IL-6-572 C/G
polymorphism, significant associations were shown in dominant model (CG+GG vs. CC: OR =0.73, 95% CI=0.62–0.86) and
in additive model (GG vs. CC, OR =0.66, 95% CI=0.46–0.96). In conclusion, genotype CC of IL-6-174 G/C and genotype GG
plus GC of IL-6-572 C/G could decrease the risk of AD.
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Introduction
As a major cause of cognitive decline in the elderly, Alzheimer’s
disease (AD) currently affects 20–30 million individuals worldwide.
It is estimated that the number of people likely to be affected will
be triple over the next 50 years throughout the world. [1,2]
Although AD is a disease associated with several risk factors such
as a series of epigenetic, genetic, endocrine, and external
environmental factors, an increasing number of experimental
evidences are suggesting a possible involvement of chronic
inflammation in onset and progression of this disease. Interleu-
kin-6 (IL-6) is a potent proinflammatory cytokine produced by
diverse kinds of cells such as leukocytes, adipocytes, endothelial
cells, fibroblasts, and myocytes. [3] It is associated with
accumulation of acute phase proteins in neuritic plaques and
amyloid precursor protein (APP) synthesis. [4] IL-6 gene, which
maps to chromosome 7p21, has been postulated to be a good
candidate genetic risk factor for AD. [5].
Two independent variants in the promoter region of IL-6
promoter (2174 G/C and 2572 C/G) have been detected.
Previous studies concerning association between IL-6-174 G/C
polymorphism and risk of AD are limited and rather conflicting.
The second IL-6 polymorphic exchange 2572 C/G (which is
identical to 2634 C/G) is not commonly analyzed as 2174 G/C.
However, previous findings suggested that 2572 C/G polymor-
phism might affect the transcription rate of the IL-6 gene, and
furthermore influence plasma levels of acute proteins such as
fibrinogen and C-reactive protein. [6,7] Recently, five previous
studies were also frequently performed on the effect of IL-6-572
C/G polymorphism on AD, but the results were conflicting.[8–12]
Two previous meta-analyses [13,14] regarding IL-6-174 G/C
polymorphisms and AD have summarized the findings from
certain studies, but a number of important studies were missed. In
addition, there is no meta-analysis on 2572 C/G polymorphisms.
Given the importance of clarifying the potential role of IL-6 gene
variants in AD and given the extensive and diverse body of
evidence available, we conducted a comprehensive systematic and
quantitative review of the evidence on the associations between
2174 G/C and 2572 C/G polymorphisms of the IL-6 gene and
the risk of AD.
Methods
Literature Search
Two reviewers independently searched studies on the associa-
tions between IL-6 polymorphisms and AD. Published studies
were identified through a computerized search of PubMed,
MEDLINE, EMBASE, and the Cochrane Library in any language
up to January 2012. The keywords were as follows: Alzheimer’s
disease, interleukin and polymorphism or variant or genotype or
SNP. The references of all identified publications were searched
for additional studies, and the PubMed option ‘‘Related Articles’’
was also used to search for potentially relevant papers. We only
included published articles written in English.
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Two reviewers independently identified potential relevant
studies and evaluated each trial based on predetermined eligibility
criteria. Studies were included if they met the following criteria: (1)
the study reported original data from case-control studies; (2) the
outcome had to be AD; (3) at least two comparison groups (AD
patient group vs. control group) and the number of subjects
possessing genotype in the AD and control groups were available;
and (4) in the case of multiple publications from the same study
group, the most complete and recent results were used.
Data Extraction
After excluding the overlap studies and including the additional
ones, this meta-analysis covered a total of 22 articles on IL-6-174
G/C polymorphism and 5 articles on IL-6-572 C/G polymor-
phism. Two authors extracted the data independently and in
duplicate. The following data were extracted from the eligible
studies: the first author’s last name, year of publication, country of
origin, ethnicity, and numbers of genotyped cases and controls.
Any disagreement was adjudicated with a third author.
Statistical Analysis
The strength of the association between the IL-6 polymorphism
and AD was measured by odds ratio (ORs) with 95% confidence
intervals (CIs). We explored the allele comparison, as well as
dominant model and recessive model. Heterogeneity among
studies was examined with I
2 statistic interpreted as the proportion
of total variation contributed by between-study variation. If there
was a statistical difference in terms of heterogeneity (I
2.50%,
P,0.05), a random-effect model was selected to combine the data.
Figure 1. PRISMA Flow Diagram.
doi:10.1371/journal.pone.0037858.g001
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the pooled OR was determined by the Z-test, and two-tailed
P,0.05 was considered as statistically significant. Relative
influence of each study on pooled estimates was assessed by
omitting one study at a time for sensitivity analysis. Evidence of
publication bias was determined by visual inspection of the funnel
plot. All statistical analyses were performed with Revman 5.0
(Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2008).
Results
Eligible Studies
In this article, the associations of IL-6 polymorphisms with AD
susceptibility were investigated using meta-analysis in a wide range
of populations (Figure 1). Twenty-seven case-control studies (22
studies on IL-6-174 G/C polymorphism[15–36] and 5 studies on
IL-6-572 C/G studies polymorphism[8–12]) met all of the
inclusion criteria and were included in the review. The detailed
characteristics of these studies are presented in Table 1.N o
evidence of publication biases were observed in Funnel plots
(available upon request). Totally 4,280 AD patients and 8,788
controls for IL-6-174 G/C polymorphism and 2,352 AD patients
and 3,715 controls for IL-6-572 C/G polymorphism were
included in the analyses. Among included studies, five stud-
ies[12,15–18] only reported GG and GC genotypes vs. CC
genotype and one [19] only reported GC and CC genotypes vs.
GG genotype information in their paper. Among the included
studies, 17 studies were on IL-6-174 G/C allele contrast and
additive model, 19 studies were on IL-6-174 G/C dominant
genetic model and 20 studies were on IL-6-174 G/C recessive
model. Though the number of studies on IL-6-572 C/G
polymorphism was small, they were also included for a compre-
hensive evaluation in this study.
Quantitative Synthesis
Allele comparison. The association between the IL-6
polymorphisms and AD were showed in Table 2 and 3. For
IL-6-174 G/C allelic contrast, the C allele was not associated with
AD (C vs. G: OR =0.95, 95% CI=0.83–1.10, P=0.53). There
was a significant difference between-study heterogeneity
(I
2=67%). No significant associations were also found for IL-6-
572 C/G allele (G vs. C: OR =0.87, 95% CI=0.69–1.10,
P=0.24). Heterogeneity was detected (I
2=68%).
Genotype comparison. The genotype frequency of the IL-6
polymorphisms between case and control groups were presented
in Table 2 and 3. For IL-6-174 G/C polymorphism, the
combined results based on all studies showed the evidence of an
association between the decreased risk of AD and the variant
genotypes in recessive model (CC vs. CG+GG: OR =0.65, 95%
CI=0.52–0.82, P=0.0003, Figure 2). There was significant
heterogeneity (I
2=65%). No associations were found in dominant
model or additive model. For IL-6-572 C/G polymorphism,
significant decreased risk was found in additive model (GG vs. CC:
OR =0.66, 95% CI=0.46–0.96, Figure 3) and dominant model
(CG+GG vs. CC: OR =0.73, 95% CI=0.62–0.86, Figure 4).
No heterogeneity was found. No associations were found in
recessive model.
Table 1. Main characteristics of selected studies.
Author Year Country Ethnicity Cases Controls
IL-6-174 G/C (rs1800795)
Bagli et al. 2000 Germany Caucasian 102 351
Bhojak et al. 2000 USA Caucasian 464 337
Pola et al. 2002 Italy Caucasian 124 134
Shibata et al. 2002 Japan Asian 128 83
Faltraco et al. 2003 Japan Caucasian 101 133
Licastro et al. 2003 Italy Caucasian 332 393
Arosio et al. 2004 Italy Caucasian 59 65
Capurso et al. 2004 Italy Caucasian 168 220
Depboylu et al. 2004 Germany Caucasian 113 108
Zhang et al. 2004 UK Caucasian 356 434
Koivisto et al. 2005 Finland Caucasian 65 542
Vural et al. 2009 Turkey Caucasian 101 138
Capurso et al. 2010 Italy Caucasian 149 298
Mansoori et al. 2010 India Asian 74 113
Combarros et al.* 2005 Spain Caucasian 234 197
Fontalba et al.* 2009 Spain Caucasian 239 165
Infante et al.* 2004 Spain Caucasian 232 201
Oijen et al. 2006 Netherlands Caucasian 483 4069
Paradowski et al. 2008 Poland Caucasian 51 36
Klimkowicz-Mrowiec et al.2010 Poland Caucasian 361 200
Papassotiropoulos et al. *1999 UK Caucasian 102 351
Mateo et al.
# 2005 Spain Caucasian 242 220
IL-6-572 C/G (rs1800796)
Eriksson et al. 2011 USA Caucasian 1255 2363
He et al. 2010 China Asian 318 324
Nishimura et al. 2004 Japan Asian 172 163
Wang et al. 2010 China Asian 341 421
Chen et al.* 2012 Taiwan Mix 266 444
*only reported GG and GC genotypes vs. CC genotype information.
#only reported GC and CC genotypes vs. GG genotype information.
doi:10.1371/journal.pone.0037858.t001
Table 2. Stratified analyses of the IL-6-174 G/C
polymorphisms on AD risk.
Outcome or
Subgroup N Cases/total I
2(%) OR (95%CI) P
C vs. G 17 6462/24902 67 0.95 (0.83, 1.10) 0.53
CC vs. GG 17 1678/6598 67 0.87 (0.65, 1.18) 0.38
CC vs. CG+GG 20 3997/13719 65 0.65 (0.52, 0.82) 0.0003
CC+GC vs. GG 19 3528/13267 90 1.01 (0.74, 1.38) 0.97
doi:10.1371/journal.pone.0037858.t002
Table 3. Stratified analyses of the IL-6-572 C/G
polymorphisms on AD risk.
Outcome or
Subgroup N Cases/total I
2(%) OR (95%CI) P
G vs. C 4 4182/10720 68 0.87 (0.69, 1.10) 0.24
GG vs. CC 4 1673/4351 24 0.66 (0.46, 0.96) 0.03
CG+GG vs. CC 5 2352/5798 0 0.73 (0.62, 0.86) 0.0002
GG vs. CG+CC 4 2086/5357 60 0.82 (0.53, 1.25) 0.35
doi:10.1371/journal.pone.0037858.t003
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According to sensitivity analysis, we found that there was no
substantial modification of our estimates after exclusion of
individual studies (data not shown), indicating that the results of
this meta-analysis were stable.
Discussion
The main finding of this meta-analysis is that genotype CC of
IL-6-174 G/C and genotype GG plus CG of IL-6-572 C/G are
potential protective factors for developing and progressing AD.
The IL-6 gene polymorphisms are widely investigated in
relation to the risk of AD. However, the results from these studies
were ambiguous, for their small sample size and unified ethnicity.
Although two meta-analysis studies have focused on 2174 G/C
polymorphism recently, none of them could give us results with all
publications. [13,14] Dai et al [13] performed a meta-analysis
based on 18 studies on the relationship between IL-6-174 G/C
and AD, and the combined results showed significant differences
in recessive model (CC versus GC + GG: OR =0.70,
95%CI=0.54–0.90). Han et al [14] showed that a borderline
statistically significant association between the IL-6-174G/C
polymorphism and AD risk in Caucasians (GG vs. CC:
Figure 2. Forest plot of AD risk associated with IL-6-174 G/C polymorphism at recessive model (CC genotypes vs. CG+GG
genotype). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of
the variance). The diamond represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0037858.g002
Figure 3. Forest plot of AD risk associated with IL-6-572 C/G polymorphism at additive model (GG genotype vs. CC genotype). The
squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The
diamond represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0037858.g003
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95%CI, 1.05–1.53, respectively) on the basis of 14 studies on
Caucasian. To the best of our knowledge, there is no meta-analysis
to explore 2572 C/G polymorphism in development and
progression of AD. To achieve a more reliable and comprehensive
conclusion on both variants, our comprehensive review covered 27
studies, including 22 on IL-6-174 G/C polymorphism[15–36] and
5o n2572 C/G studies polymorphism[8–12], versus 14 to 18
studies in previous reviews. With 6,632 AD patients and 12,503
controls for IL-6-174 and -572 polymorphisms investigations
included, the results from our studies consent to previous meta-
analyses and may confirm that the IL-6 2174G/C polymorphism
may be a protective factor for the development of AD.
Because heterogeneity was found among the studies, we
employed random-effect model. Then, a sensitivity analysis was
performed by removing one study for each time and re-running
the model to determine the effect on the overall estimate. The
estimates changed quite little, strengthening the results from this
meta-analysis. No publication bias was shown, also strengthening
our results.
As inflammation is involved in the pathogenesis of AD, IL-6 has
been implicated in both the development and progression through
accumulation of acute phase proteins in plaques and elevation of
amyloid precursor protein synthesis in experimental and human
AD. [4] Since the 2174 C allele and 2572 G allele in the
promoter region of IL-6 gene were reported to reduce IL-6 gene
expression and IL-6 levels in the blood and brain from AD [8,23],
investigations on these and related variants have obtained a steady
rise in AD studies during recent decades. Our findings showed that
IL-6 polymorphism was associated with a decreased risk of AD,
which may confirm the biologically plausible described above.
This meta-analysis has pooled all the available results from the
case–control studies, which has significantly increased the
statistical power. However, some limitations of this meta-analysis
should be acknowledged. First, AD is a complex disease that
results of combined effects of multifactor, including inherited and
environmental factors. Some environmental factors may strongly
influence the development of AD. Lacking of considering these
factors may affect the significance for the independent role of IL-6
polymorphisms in AD development. Second, the network of
cytokines is complex and variants of other pro-inflammatory
cytokines may exert their complex and interacting functions with
each other. No regard of these factors may cause serious
confounding bias. Third, the number of current studies on IL-6-
572 C/G is relative small. Thus, investigations involving more
subjects of different races are needed to confirm the effect and
then another meta-analysis should be necessary for a more reliable
evaluation on their associations. Fourth, the heterogeneity
observed in the relationship between 2174 G/C polymorphism
and AD, even when analyzed by ethnicity and a sensitivity
analysis. Finally, we reviewed only published studies.
In conclusion, this meta-analysis detected significant associa-
tions between IL-6-174 G/C and 2572 C/G polymorphisms and
AD. Genotype CC of IL-6-174 G/C and genotype GG plus CG of
2572 C/G could decrease the risk of AD. To better understand
the potential mechanism for AD in humans, large well-designed
cohort studies are needed to confirm these associations and further
researches should be carried out to explore the effect of genetic
networks, environmental factors, individual biological character-
istics and their mutual interactions.
Author Contributions
Conceived and designed the experiments: SB. Performed the experiments:
H-PQ Z-YQ S-RD S-RW. Analyzed the data: H-PQ Z-YQ. Contributed
reagents/materials/analysis tools: S-QW. Wrote the paper: H-PQ.
Improved the English of the manuscript: S-QW.
References
1. Querfurth HW, LaFerla FM (2011) Alzheimer’s disease. New England Journal
of Medicine. 362: 329–344.
2. Alzheimer’s Association (2009) 2009 Alzheimer’s disease facts and figures.
Alzheimers Dement. 5(3): 234–270.
3. Nishimoto N (2010) Interleukin-6 as a therapeutic target in candidate
inflammatory diseases. Clin Pharmacol Ther. 87(4): 483–7.
4. Ge YW, Lahiri DK (2002) Regulation of promoter activity of the APP gene by
cytokines and growth factors: implications in Alzheimer’s disease. Ann N Y Acad
Sci. 973: 463–7.
5. Serretti A, Olgiati P, De Ronchi D (2007) Genetics of Alzheimer’s disease. A
rapidly evolving field. J Alzheimers Dis. 12(1): 73–92.
6. Paik JK, Kim OY, Koh SJ, Jang Y, Chae JS, et al. (2007) Additive effect of
interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on
serum CRP concentration and other cardiovascular risk factors.Clin Chim Acta.
380(1–2): 68–74.
7. Wong LY, Leung RY, Ong KL, Cheung BM (2007) Plasma levels of fibrinogen
and C-reactive protein are related to interleukin-6 gene 2572C .G
polymorphism in subjects with and without hypertension. J Hum Hypertens.
21: 875–82.
Figure 4. Forest plot of AD risk associated with IL-6-572 C/G polymorphism at dominant model (CG+GG genotype vs. CC genotype).
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance).
The diamond represents the summary OR and 95% CI.
doi:10.1371/journal.pone.0037858.g004
IL-6 Polymorphisms and AD
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e378588. He MX, Yang WL, Zhang MM, Lian YJ, Hua HY, et al. (2010) Association
between interleukin-6 gene promoter 2572C/G polymorphism and the risk of
sporadic Alzheimer’s disease. Neurol Sci. 31: 165–8.
9. Nishimura M, Sakamoto T, Kaji R, Kawakami H (2004) Influence of
polymorphisms in the genes for cytokines and glutathione S-transferase omega
on sporadic Alzheimer’s disease. Neurosci. Lett. 368: 140–3.
10. Eriksson UK, Pedersen N, Reynolds CA, Hong MG, Prince JA, et al. (2011)
Associations of gene sequence variation and serum levels of C-reactive protein
and interleukin-6 with Alzheimer’s disease and dementia. Journal of Alzheimer’s
Disease. 23: 1–3.
11. Wang M, Jia J (2010) The interleukin-6 gene 2572C/G promoter polymor-
phism modifies Alzheimer’s risk in APOEe4 carriers. Neuroscience Letters. 482:
260–3.
12. Chen SY, Chen TF, Lai LC, Chen JH, Sun Y, et al. (2012) Sequence variants of
interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset
Alzheimer’s disease. J Neuroinflammation. 9(1): 21. [Epub ahead of print].
13. Dai L, Liu D, Guo H, Wang Y, Bai Y (2011) Association between polymorphism
in the promoter region of Interleukin 6 (2174 G/C) and risk of Alzheimer’s
disease: a meta-analysis. J Neurol. [Epub ahead of print].
14. Han XM, Wang CH, Sima X, Liu SY (2011) Interleukin-6-174G/C
polymorphism and the risk of Alzheimer’s disease in Caucasians: A meta-
analysis. Neurosci Lett. 504(1): 4–8.
15. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, et al. (1999) A
genetic variation of the inflammatory cytokine interleukin-6 delays the initial
onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol. 45(5):
666–8.
16. Infante J, Sanz C, Ferna ´ndez-Luna JT, Llorca J, Berciano J, et al. (2004) Gene–
gene interaction between interleukin-6 and interleukin-10 reduces AD risk.
Neurology. 63(6): 1135–6.
17. Combarros O, Infante J, Llorca J, Pen ˜a N, Ferna ´ndez-Viadero C, et al. (2005)
Interaction between interleukin-6 and intercellular adhesion molecule-1 genes
and Alzheimer’s disease risk. J Neurol. 252: 485–7.
18. Fontalba A, Gutie ´rrez O, Llorca J, Mateo I, Mateo I, et al. (2009) Gene-gene
interaction between CARD8 and interleukin-6 reduces Alzheimer’s disease risk.
J Neurol. 256(7): 1184–6.
19. Mateo I, Infante J, Rodrı ´guez E, Berciano J, Combarros O, et al. (2006)
Interaction between dopamine beta-hydroxylase and interleukin genes increases
Alzheimer’s disease risk. J Neurol Neurosurg Psychiatry. 77(2): 278–9.
20. Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Luise Rao M, et al. (2000)
Association between an interleukin-6 promoter and 39 flanking region haplotype
and reduced Alzheimer’s disease risk in a German population. Neurosci Lett.
283(2): 109–12.
21. Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI (2000) Genetic polymor-
phisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer’s
disease. Neurosci Lett. 288(1): 21–4.
22. Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, et al. (2004)
Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for
Alzheimer’s disease. Neurobiol Aging. 25(8): 1009–15.
23. Capurso C, Solfrizzi V, D’Introno A, Colacicco AM, Capurso SA, et al. (2004)
Interleukin 6–174 G/C promoter gene polymorphism and sporadic Alzheimer’s
disease: geographic allele and genotype variations in Europe. Exp Gerontol.
39(10): 1567–73.
24. Capurso C, Solfrizzi V, Colacicco AM, D’Introno A, Frisardi V, et al. (2010)
Interleukin 6–174 G/C promoter and variable number of tandem repeats
(VNTR) gene polymorphisms in sporadic Alzheimer’s disease. Prog Neuropsy-
chopharmacol Biol Psychiatry. 34: 177–82.
25. Depboylu C, Lohmu ¨ller F, Gocke P, Du Y, Zimmer R, et al. (2004) An
interleukin-6 promoter variant is not associated with an increased risk for
Alzheimer’s disease. Dement Geriatr Cogn Disord. 17(3): 170–3.
26. Faltraco F, Bu ¨rger K, Zill P, Teipel SJ, Mo ¨ller HJ, et al. (2003) Interleukin-6-174
G/C promoter gene polymorphism C allele reduces Alzheimer’s disease risk. J
Am Geriatr Soc. 51(4): 578–9.
27. Koivisto AM, Helisalmi S, Pihlajama ¨ki J, Moilanen L, et al. (2005) Interleukin-6
promoter polymorphism and late-onset Alzheimer’s disease in the Finnish
population. J Neurogenet. 19(3–4): 155–61.
28. Licastro F, Grimaldi LM, Bonafe ` M, Martina C, Olivieri F, et al. (2003)
Interleukin-6 gene alleles affect the risk of Alzheimer’s disease and levels of the
cytokine in blood and brain. Neurobiol Aging. 24(7): 921–6.
29. Mansoori N, Tripathi M, Alam R, Luthra K, Ramakrishnan L, et al. (2010) IL-
6-174 G/C and ApoE gene polymorphisms in Alzheimer’s and vascular
dementia patients attending the cognitive disorder clinic of the All India Institute
of Medical Sciences, New Delhi. Dement Geriatr Cogn Disord. 30(6): 461–8.
30. van Oijen M, Arp PP, de Jong FJ, Hofman A, Koudstaal PJ, et al. (2006)
Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene
and risk of dementia. The Rotterdam Study. Neurosci Lett. 402(1–2): 113–7.
31. Pola R, Flex A, Gaetani E, Lago AD, Gerardino L, et al. (2002) The 2174 G/C
polymorphism of the interleukin-6 gene promoter is associated with Alzheimer’s
disease in an Italian population [corrected]. Neuroreport. 13(13): 1645–7.
32. Shibata N, Ohnuma T, Takahashi T, Baba H, Ishizuka T, et al. (2002) Effect of
IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype
association study in Japanese cases. Am J Med Genet. 2002; 114(4): 436–9.
33. Vural P, Deg ˘irmenciog ˘lu S, Parildar-Karpuzog ˘lu H, Dog ˘ru-Abbasog ˘lu S,
Hanagasi HA, et al. (2009) The combinations of TNFalpha-308 and IL-6-174 or
IL-10-1082 genes polymorphisms suggest an association with susceptibility to
sporadic late-onset Alzheimer’s disease. Acta Neurol Scand. 120(6): 396–401.
34. Zhang Y, Hayes A, Pritchard A, Thaker U, Haque MS, et al. (2004) Interleukin-
6 promoter polymorphism: risk and pathology of Alzheimer’s disease. Neurosci
Lett. 362(2): 99–102.
35. Klimkowicz-Mrowiec A, Wołkow P, Spisak K, Spisak K, Maruszak A, et al.
(2010) Interleukin-6 gene (2174 C/G) and apolipoprotein E gene polymor-
phisms and the risk of Alzheimer disease in a Polish population. Neurol
Neurochir Pol. 44(6): 537–41.
36. Paradowski B, Celczyn ´ska D, Dobosz T, Noga L (2008) Polymorphism 174 G/C
of interleukin 6 gene in Alzheimer’s disease–preliminary report. Neurol
Neurochir Pol. 42(4): 312–5.
IL-6 Polymorphisms and AD
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37858